 | Up a level |
Number of items: 1.
Dreger, P., Boumendil, A., Koster, L., Scheid, C., Passweg, J., Veelken, H., Cahn, Y., Collin, M., Wilson, K., Bazarbachi, A., Mayer, J., Corradini, P., Hunault-Berger, M., Parody Porras, R., Gribben, J., Bittenbring, J., Wolff, D., Charbonnier, A., Cambier, N., Montoto, S., Kroeger, N. and Schetelig, J. (2017). No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties. Bone Marrow Transplant., 52. S. S424 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365